Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9740903 | 0.80 | SMN1; SMN2 (0.55) | SMN1; SMN2MAPTRAB9ANPC1TP53 | |
| SCHEMBL21222557 | 0.77 | TP53 (0.66) | SMN1; SMN2MAPTRAB9ANPC1TP53 | |
| SCHEMBL8356753 | 0.77 | TP53 (0.46) | SMN1; SMN2MAPTTP53ALDH1A1GAA | |
| SCHEMBL6992440 | 0.76 | TP53 (0.40) | SMN1; SMN2MAPTRAB9ANPC1TP53 | |
| SCHEMBL4714870 | 0.74 | RAB9A (0.69) | SMN1; SMN2MAPTRAB9ANPC1TP53 | |
| SCHEMBL4459490 | 0.74 | HDAC1 (0.62) | SMN1; SMN2MAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL2442194 | 0.74 | TP53 (0.47) | SMN1; SMN2MAPTTP53ALDH1A1GAA | |
| SCHEMBL2443550 | 0.72 | TP53 (0.42) | SMN1; SMN2MAPTTP53ALDH1A1CSNK2A1 | |
| SCHEMBL21562086 | 0.71 | RAB9A (0.41) | SMN1; SMN2MAPTRAB9ANPC1TP53 | |
| SCHEMBL3786921 | 0.71 | POLB (0.66) | SMN1; SMN2MAPTRAB9ANPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911372-B2 | Compounds | CTXT PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-20230134869-A1 | CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230061891-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-4129987-A1 | CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
| US-20210355105-A1 | REGULATOR OF NITROGEN-CONTAINING HETEROAROMATIC DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2021-11-18 | — | — | US | disclosed |
| US-11111229-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210213004-A1 | Compounds | CTXT PTY LTD (AU) | 2021-07-15 | — | — | US | disclosed |
| EP-3813813-A1 | COMPOUNDS | CTXT Pty Limited (AU) | 2021-05-05 | — | — | EP | disclosed |
| EP-3799872-A1 | TETRAHYDROQUINOLINE DERIVATIVES FOR USE AS BET INHIBITORS | Forma Therapeutics, Inc. (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-3071203-B1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS INC (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20160256448-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9388161-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150232445-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
| EP-1737463-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | disclosed |
| EP-1863805-A1 | PYRIMIDINE COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2007-12-12 | — | — | EP | disclosed |
| CN-1917879-A | Pyrimidines with tie2 (tek) activity | ASTRAZENECA AB (SE) | 2007-02-21 | — | — | CN | disclosed |
| EP-1737463-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | AstraZeneca AB (SE) | 2007-01-03 | — | — | EP | disclosed |
| WO-2006082373-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
| WO-2005060970-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160256448-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | SMN1; SMN2 4712/4885MAPT 3708/4885RAB9A 1876/4885 |
| US-20210355105-A1 | REGULATOR OF NITROGEN-CONTAINING HETEROAROMATIC DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | PTPN11, PTPN1, PTPN7 | SMN1; SMN2 2016/4885MAPT 3446/4885RAB9A 3860/4885 |
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | TIE1, TEK, TEKT1 | SMN1; SMN2 3209/4885MAPT 1508/4885RAB9A 4632/4885 |
| US-11111229-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | BRD4, BRD3, BRD1 | SMN1; SMN2 4712/4885MAPT 3708/4885RAB9A 1876/4885 |
| US-20150232445-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | SMN1; SMN2 4712/4885MAPT 3708/4885RAB9A 1876/4885 |
| US-20230061891-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | SMN1; SMN2 4712/4885MAPT 3708/4885RAB9A 1876/4885 |
| US-20210213004-A1 | Compounds | SLC10A1, ABCB11, REN | SMN1; SMN2 1164/4885MAPT 1236/4885RAB9A 323/4885 |
| US-20230134869-A1 | CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES | PTPN22, PTPN2, PTPN5 | SMN1; SMN2 678/4885MAPT 975/4885RAB9A 2164/4885 |
| US-11911372-B2 | Compounds | SLC10A1, ABCB11, REN | SMN1; SMN2 1164/4885MAPT 1236/4885RAB9A 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.